Table 1

Patient and procedural characteristics according to loading P2Y12 inhibitor

CharacteristicsPrasugrel or ticagrelor, n=1035Clopidogrel, n=1069p Value
Age, years60.0±12.163.1±13.3<0.0001
Women222 (21.4)272 (25.4)0.031
Diabetes142 (13.7)136 (12.7)0.50
Current smoker (within past 30 days)439 (42.5)466 (43.6)0.009
Hypertension434 (42.0)470 (44.0)0.36
Previous myocardial infarction75 (7.3)105 (9.8)0.035
Previous PTCA/PCI87 (8.4)102 (9.5)0.37
Previous CABG18 (1.7)26 (2.4)0.27
Hyperlipidaemia*424 (41.0)337 (31.5)<0.0001
Country<0.0001
 France554 (53.5)233 (21.8)
 Netherlands251 (24.3)507 (47.4)
 Germany120 (11.6)93 (8.7)
 Denmark85 (8.2)61 (5.7)
 Other†25 (2.4)175 (16.4)
Killip class0.11
 I851/921 (92.4)929/986 (94.2)
 II to IV70/921 (7.6)57/986 (5.8)
Creatinine clearance<0.0001
 ≤60 mL/min123/924 (13.3)168/991 (17.0)
 >60 mL/min801/924 (86.7)823/991 (83.0)
Anaemia106/918 (11.5)151/971 (15.6)0.011
P2Y12 loading dose before angiography882/1012 (87.2)953/1007 (94.6)<0.0001
Pre-PCI TIMI 3 flow207/923 (22.4)178/899 (19.8)0.020
PCI performed928/1035 (89.7)918/1069 (85.9)0.0081
Radial access608/1027 (59.2)396/1037 (38.2)<0.0001
Thrombectomy308/928 (33.2)291/918 (31.7)0.49
Post-PCI TIMI 3 flow884/923 (95.8)844/898 (94.0)0.35
Procedural complication57/928 (6.1)66/918 (7.2)0.37
Failed procedure10/928 (1.1)24/918 (2.6)0.014
Anticoagulant used0.043
 Unfractionated heparin444/1048 (42.4)526/1079 (48.7)
 Low-molecular-weight heparin73/1048 (7.0)20/1079 (1.9)
 Bivalirudin531/1048 (50.6)533/1079 (49.4)
Glycoprotein IIb/IIIa inhibitor use431/1035 (41.6)431/1069 (40.3)0.54
 Bailout119/431 (27.6)79/431 (18.3)
 Routine312/431 (72.4)352/431 (81.7)
  • Data are presented as n (%), n/N (%) or mean±SD.

  • *Diagnosis of hyperlipidaemia or use of a lipid-lowering therapy.

  • †Austria, Czech Republic, Italy, Poland, Slovenia.

  • CABG, coronary artery bypass graft; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty; TIMI, Thrombolysis In Myocardial Infarction.